Related Experiment Video
Updated: Aug 7, 2025
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Albert Jang1, Ayse T Kendi2, Oliver Sartor3
1Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
Abstract:
Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in current therapies are needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer given its increased expression on the surface of the prostate cancer cells. PSMA small molecule binders include PSMA-617 and PSMA-I&T and monoclonal antibodies such as J591. These agents have been linked to different radionuclides including beta-emitters such as lutetium-177 and alpha-emitters such as actinium-225. The only regulatory-approved PSMA-targeted radioligand therapy (PSMA-RLT) to date is lutetium-177-PSMA-617 in the setting of PSMA-positive metastatic castration-resistant prostate cancer that has failed androgen receptor pathway inhibitors and taxane chemotherapy. This approval was based on the phase III VISION trial. Many other clinical trials are evaluating PSMA-RLT in various settings. Both monotherapy and combination studies are underway. This article summarizes pertinent data from recent studies and provides an overview of human clinical trials in progress. The field of PSMA-RLT is rapidly evolving, and this therapeutic approach will likely play an increasingly important role in the years to come.
Insights
Prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT) shows promise for metastatic prostate cancer. Ongoing trials explore its use in various settings, offering new hope for improved patient outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Metastatic prostate cancer remains largely incurable, necessitating novel therapeutic strategies.
- Prostate-specific membrane antigen (PSMA) is overexpressed on prostate cancer cells, making it a viable therapeutic target.
- Current treatments offer limited efficacy, highlighting the need for improved therapies.
Purpose of the Study:
- To summarize recent data on PSMA-targeted radioligand therapy (PSMA-RLT).
- To provide an overview of ongoing clinical trials evaluating PSMA-RLT.
- To discuss the evolving role of PSMA-RLT in prostate cancer treatment.
Main Methods:
- Review of recent studies and clinical trial data.
- Focus on PSMA small molecule binders (e.g., PSMA-617) and monoclonal antibodies (e.g., J591).
- Inclusion of radionuclides like lutetium-177 and actinium-225.
Main Results:
- Lutetium-177-PSMA-617 is the first approved PSMA-RLT for metastatic castration-resistant prostate cancer post-standard therapy.
- The VISION trial supported the approval of lutetium-177-PSMA-617.
- Numerous clinical trials are investigating PSMA-RLT in diverse settings, including monotherapy and combination approaches.
Conclusions:
- PSMA-RLT is a rapidly advancing field with significant potential in prostate cancer management.
- Further research and clinical trials are crucial to optimize PSMA-RLT efficacy and application.
- PSMA-RLT is expected to become increasingly important in treating metastatic prostate cancer.
